BMJ11h
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ2d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ3d
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This ...
BMJ4d
THU0178 Long term safety profile of methotrexate in patients with ra in routine care
Background Methotrexate is the anchor drug used most widely as monotherapy or combination therapy with other DMARDS & biologics in treatment of RA. It is widely perceived by clinicians to have ...
BMJ8d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ12d
Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade
Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...
BMJ13d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ21d
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up
Correspondence to Professor Chunde Bao, Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; baochunde_1678{at}126.com; Professor Liangjing Lu ...
BMJ23d
CD109 regulates the inflammatory response and is required for the pathogenesis of rheumatoid arthritis
2 Department of Pathology, Shandong University Medical School, Jinan, China Correspondence to Dr Lin Wang, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Research Center for ...
BMJ28d
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
Objectives Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) share many clinical manifestations and serological features. The aim of this study was to ...
BMJ1mon
Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake
A clinical guideline is a document with the aim of guiding decisions based on evidence regarding diagnosis, management and treatment in specific areas of healthcare. Specific to rheumatic and ...